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OBJECTIVE—Diabetes mellitus (DM) is a complex, chronic disease requiring active self-
management and coordinated care. This study aimed to evaluate the relationship between
schizophrenia and risk of preventable, acute DM complications.
RESEARCH DESIGN AND METHODS—With the use of administrative data, a retro-
spective study assessed acute DM complications (emergency department [ED] visits or hospi-
talization for hypo- or hyperglycemia and hospital admissions for infections) among Ontario
residents ages 18–50 with schizophrenia and newly diagnosed DM between 1995 and 2005,
comparingpeoplewithandwithoutpre-existingschizophrenia.PrimaryoutcomewasEDvisitor
hospitalization for hypo- or hyperglycemia. Secondary outcome was the ﬁrst of either the pri-
mary outcome or hospitalization for infection.
RESULTS—People with schizophrenia had a 74% greater risk of requiring a hospital visit for
hypo- or hyperglycemia (hazard ratio [HR] = 1.74, 95% conﬁdence interval 1.42–2.12) com-
pared with those without schizophrenia. The risk was similar when the outcome included in-
fection (HR = 1.62, 95% CI 1.39–1.89). Outcomes remained signiﬁcant after adjustment for
baseline characteristics.
CONCLUSIONS—People with schizophrenia are at greater risk for developing an acute
complication of DM. Understanding this relationship will direct future studies assessing barriers
to care and implementation of individualized approaches to care for this population.
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D
iabetes mellitus (DM) is a serious
chronic condition associated with
potentially devastating complica-
tions. Chronic poor control of DM can
lead to macrovascular and microvascular
complications. Suboptimal DM manage-
ment can result in metabolic decompen-
sation acutely, such as states of extreme
hypo- or hyperglycemia and the asso-
ciated metabolic derangements. Such
events have been classiﬁed as ambulatory-
care sensitive conditions for which hos-
pitalization is thought to be avoidable
through interventions and early disease
management delivered in an ambulatory
care setting. High rates of hospital visits
for conditions considered ambulatory-
care sensitive may provide evidence of
problems with access to healthcare, in-
adequate care, and resources or lack of
integration between medical services.
Risk factors for poorer DM control
and DM complications include nonwhite
ethno-racial groups, low socioeconomic
status (SES), and certain geographic loca-
tions (1–6). Another potentially vulnera-
ble group includes people with other
serious medical conditions, such as
schizophrenia.Peoplewithschizophrenia
have an increased risk of developing DM
compared with the general population
(7–10) and are also less likely to receive
adequate care for other medical condi-
tions (11). The relationship between DM
and schizophrenia is complex and in-
corporates a number of factors, including
the understanding and management of
DM by patients and their mental health
care providers and an acute care system
notwelldesignedtosupportpatientswith
comorbid chronic medical and psychiat-
ric illnesses. The coexistence of schizo-
phrenia may increase the inherent social
andeconomicchallengestoachievingDM
targets, leading to an increase in the oc-
currence of acute DM complications.
Therefore, the current study examines
the relationship between acute complica-
tions of DM in individuals with and with-
out schizophrenia in a public healthcare
system where ﬁnancial barriers to access
should be reduced.
RESEARCH DESIGN AND
METHODS—A population-based ret-
rospective matched cohort study was
conducted, evaluating the relationship
betweenschizophreniaandacutecompli-
cations of DM. Individuals with newly
diagnosed DM were drawn from the
Ontario Diabetes Database, a validated
database, derived from administrative
data sources, with information on all
Ontario residents diagnosed with DM (12).
Ontario residents ages 18 to 50 years, di-
agnosed with DM between April 1, 1996,
and March 31, 2005, were included.
Older patients were excluded to minimize
theimpactofothermedicalcomorbidities,
which might also contribute to the princi-
pal outcome of emergency department
(ED) visits. The index date was the date
of diagnosis of DM.
Within this population, two cohorts
wereidentiﬁed—oneofpatientswithpre-
existing schizophrenia at the time of
diagnosis of DM and one of matched
individuals with DM but free of schizo-
phrenia. Cases of schizophrenia were
identiﬁed either by having at least two
hospitalizations for schizophrenia or by
having one hospitalization and one phy-
sician service claim in the Ontario Health
InsurancePlan(OHIP)databasenotrelated
to the hospitalization for schizophrenia
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ORIGINAL ARTICLEafter April 1, 1992 and before the diagno-
sisofDM.Hospitalizationswereidentiﬁed
in the Canadian Institute for Health
Informationdatabase (CIHI-DAD).Ahos-
pitalization was attributed to schizophre-
nia if the most responsible diagnosis
recorded in the discharge abstract was
for schizophrenia using ICD-9 CM =
295.0–2 9 5 . 9o rI C D - 1 0=F20.03 to
F20.93 coding.
Controls were identiﬁed as people
without medical records for schizophre-
nia at any time during the observation
period (April 1, 1992, through March 31,
2006) and were matched to schizophre-
nia cases on age (6 2 years), sex, geo-
graphic region, and both area and
individual-level SES. Ecologic attribution
ofSESfromcensusdatawasused tomatch
neighborhood level SES of cases and con-
trols (13). In addition, an individual-level
indicator of low SES was used for match-
ing.TheMinistryofHealthandLong-term
Carecoversthecostofprescriptiondrugs
for people receiving social assistance
(welfare or disability support). Coverage
thus provides a binary measure of low
SES at the patient level. Individuals
wereconsideredtohavequaliﬁedforcov-
erage if they received any reimbursed
drug beneﬁts under the Ontario Drug
Beneﬁt Program in the year before the in-
dex date or within 6 months after the di-
agnosis of DM. Up to three matched
controls were sought for each case of
schizophrenia.
The primary outcome was the ﬁrst
occurrence of an acute complication of
DM, deﬁned by a hospitalization or ED
visit for hyperglycemia or hypoglycemia.
Secondary outcomes included the ﬁrst
occurrenceofeitherhospitalizationorED
visit for hyper- or hypoglycemia or hos-
pital admission for any of the following
infections: skin and soft tissue infection,
bacteremia, pneumonia, or urinary tract
infection, and death from any cause.
Before 2002, ED visit records were
not available apart from physician service
(OHIP) claims. Diagnostic information
on these claims was inadequate to distin-
guish hyperglycemia from hypoglycemia.
ED visits were included in the outcome
if the OHIP claim had a diagnosis code
250 or 251. From April 1, 2002, onward,
eligible ED visits were identiﬁed in the
National Ambulatory CareReportingSys-
tem record, by diagnosis codes in any
position and contained the following
(E10–E14)0.0 or (E10–E14)0.1. Hospital-
izations were determined using the CIHI-
DAD record, using the following codes:
before April 1, 2002, records in which the
most responsible diagnosis was 250.0–
250.3 or from April 1, 2002, onward,
records in which the most responsible di-
agnosiswas(E10-E14)0.0or(E10-E14)0.1.
The secondary outcomes were iden-
tiﬁed by the ﬁr s td a t et h a ta ni n d i v i d u a l
developed either the primary outcome or
had a hospital admission with one of the
listed infections as the most responsible
diagnosis (Supplementary Table 1).
Outcomes were measured from the
indexdateuntiltheendoftheobservation
period (March 31, 2006). Individuals
were censored at death, migration out of
province, or development of the outcome
of interest.
Baseline covariates at index were re-
corded. A usual care provider was iden-
tiﬁedifinthe2yearsbeforetheindexdate
there were more than two physician visits
and at least 50% of thesevisitswere to the
same physician. Comorbidity was esti-
mated using the Johns Hopkins Col-
lapsed Aggregated Diagnosis Groups
(CADGs) (14). In this study, CADG cate-
gory 5 was used (chronic unstable medi-
cal disease). Resource Utilization Band
(RUB), a predictor of healthcare expendi-
ture for a given individual, was also used
as a measure of comorbidity. The annual-
ized numbers of physician visits for pri-
mary care physicians, psychiatrists, and
internal medicine specialists between the
index date and both the ﬁrst primary and
secondary outcome event were used as a
measure of healthcare utilization.
All statistical analyses were per-
formed using SAS version 9.1, and statis-
tical signiﬁcance was set at a two-sided
P value less than 0.05.
Overall proportions or means, me-
dians, ranges, and 95% conﬁdence inter-
vals were calculated for the covariates by
study group. Comparisons were made
between the groups accounting for strata,
since the groups were matched in a ratio
of 1:3.
Frequency of a ﬁrst hospital visit for
hypo- orhyperglycemiaby schizophrenia
status was described. Survival analysis
using a Cox proportional hazard model
was estimated using time from index to
the ﬁrst outcome. A series of univariate Cox
models were ﬁt to assess the individual
effects of each of the covariates (including
schizophrenia) on the outcome. A multivar-
iable Cox model was then ﬁt to determine
thehazardratio(HR)associatedwithcoexis-
tence of schizophrenia after adjustment for
potential confounders. A similar analysis
was repeated for the secondary composite.
The frequency of death was calcu-
lated and proportions calculated for each
group.
Before study initiation, ethics ap-
proval was obtained from the Institu-
tional Review Board at Sunnybrook
Health Sciences Centre (Toronto, ON,
Canada).
RESULTS—There were 1,262 newly
diagnosed cases of DM among people
with pre-existing schizophrenia in On-
tario between 1996 and 2005 and 3,771
matched controls. People with schizo-
phrenia (99.13%) matched to three peo-
ple in the comparison group without
schizophrenia,withtheremaindermatched
to one or two controls. The ﬁnal analysis
included 5,033 individuals.
Baseline data for the groups are com-
pared in Table 1. The mean age at index
was 38.8 years. The groups were well
matchedontheindicatedvariables.Com-
paredwithpeoplewithoutschizophrenia,
those with schizophrenia were more
likelytohaveseenaprimarycareprovider
preceding the diagnosis of diabetes but
less likely to have a usual care provider.
They were signiﬁcantly more likely to be
placed in a higher RUB. There was no dif-
ference in the proportion of people with a
chronic unstable medical illness.
Among people with schizophrenia,
over 12% required at least one hospital
visit for hypo- or hyperglycemia, com-
paredwithabout7%inthegroupwithout
s c h i z o p h r e n i a( T a b l e2 ) .T h e r ew e r ea
signiﬁcantly higher proportion of indi-
viduals with the composite secondary
outcomeinthegroupwithschizophrenia.
Analysisoftheinfectionratesrevealedthe
greatest difference in the hospital admis-
sion rate for pneumonia (Table 2). Indi-
viduals with schizophrenia had an almost
twofold increased death rate (P ,
0.0001).
Among the people who had devel-
oped an outcome, there was a signiﬁcant
difference between the number of annu-
alized visits to a primary care physician
between index and the primary outcome
and between index and the secondary
outcome (data not presented), indicating
that individuals with schizophrenia had
higher utilization rates. The same rela-
tionship was found when evaluating an-
nualized visits to a psychiatrist between
the index and each outcome. With re-
spect to annualized visits to an internal
medicine specialist, there was no signiﬁ-
cant difference between the groups for
either event.
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ards analysis comparing the rate ratio of
developing the primary outcome, pres-
enceofschizophreniawasassociatedwith
anunadjustedHRof1.74(Fig.1).Schizo-
phrenia was associated with a HR of 1.62
for the secondary outcome (Fig. 1). After
testing for collinearity was done, none of
the proposed variables were highly corre-
lated.Therefore,multivariateanalysesad-
justed for variablesthat may inﬂuence the
association between schizophrenia and
each outcome (Table 3). Presence of
schizophrenia yielded an adjusted HR
of 1.68 for the primary outcome and
1.50 for the composite secondary out-
come.
CONCLUSIONS—Among people
with newly diagnosed DM in Ontario,
those with a pre-existing diagnosis of
schizophrenia had a signiﬁcantly higher
rate of hospital visits for hypo- or hyper-
glycemia, compared with similar people
without schizophrenia. Schizophrenia
was also associated with a signiﬁcantly
increased risk of hospitalization for
infection. Finally, there was an almost
twofold higher mortality rate among
individuals with schizophrenia.
DM is a complex condition that is
challenging to manage. Coexisting schizo-
phrenia poses additional difﬁculty in
achieving DM targets and minimizing ad-
verse outcomes. This study has demon-
strated that individuals with both newly
diagnosed DM and schizophrenia are vul-
nerable,sufferinganincreasedrateofacute
complications of DM compared with sim-
ilarpeoplewithoutschizophrenia.Further-
more,theincreaseinadverseoutcomeswas
not because of ﬁnancial barriers to access,
since this study was conducted in a uni-
versal publicly funded system. Indeed, it
appears that these outcomes occurred de-
spite an increased frequency of outpatient
visitsamongthegroupwithschizophrenia.
This ﬁnding indicates that access to out-
patient visits is not the issue but that
physicianvisitsforindividualswithschizo-
phrenia may not be providing the appro-
priate components of DM care.
Althoughpatientlevelfactors,suchas
the effects of cognitive and behavioral
disturbances and medications, make the
management of DM in individuals with
schizophrenia more complex, provider
level factors may also be important. It is
possible that healthcare providers focus
on other patient needs, neglecting so-
matic health (15). Individual physicians
may feel ill-equipped to address both
mental health and physical health. Both
psychiatrists and primary care physicians
work under great time constraints, limit-
ing their availability to provide additional
services (16). Stigmatization of psychiat-
ric conditions can impact provision of
healthcare, since providers may not be
convinced that health and wellness are
feasible among individuals with schizo-
phrenia. However, data suggest that peo-
ple with serious mental illness are as able
as the general population to achieve ad-
herence to dietary recommendations and
weight loss (17–19).
The Ontario medical system is not
unique with respect to the lack of in-
tegration leading to fragmented care of
people with medical and mental health
issues. There are several types of separa-
tionbetweenthetwosystemsthatcarefor
medical health and mental health: geo-
graphic, organizational, cultural, and ﬁ-
nancial (20,21). In contrast, in a system
such as the Veteran’sA f f a i r ss y s t e m ,
which is highly integrated, there is less
of a discrepancy in DM care (22). In
fact, it has been suggested that people
with DM and serious mental illness may
indeed fare better, perhaps due to a
more integrated team of healthcare
Table 1—Baseline characteristics by presence of schizophrenia
Variable
Schizophrenia
(N = 1,262)
No schizophrenia
(N = 3,771)
Age at diagnosis (years) 38.78 (7.62) 38.90 (7.62)
Women (%) 46.99 47.10
Income quintile (%)
1 39.26 39.33
2 24.02 24.06
3 15.49 15.46
4 12.62 12.53
5 8.61 8.62
ODB coverage (%) 78.37 78.28
Number of visits to PC provider within year before
DM diagnosis 11 (0–179) 7 (0–151)
Presence of a usual care provider (%) 37.64 42.03
CADG5 (chronic medical unstable) 29.48 29.70
RUB category (%)
0, 1, or 2 0.48 10.03
3 41.52 56.85
4 35.66 24.16
5 22.35 8.96
Data are means 6 SD, median (range), and percent. ODB, Ontario Drug Beneﬁt Program. PC, primary care.
Table 2—Outcomes by presence of schizophrenia
Outcome
Schizophrenia
(N = 1,262)
No schizophrenia
(N = 3,771)
Primary outcome (%)* 158 (12.52) 277 (7.35)
Secondary outcome (%)** 268 (21.24) 513 (13.60)
Infection 152 (12.04) 295 (7.82)
Skin/soft tissue infection 48 (3.80) 98 (2.60)
Bacteremia 28 (2.22) 68 (1.80)
Pneumonia 36 (2.85) 61 (1.62)
Urinary tract infection 48 (3.80) 101 (2.68)
Death (%) 48 (3.80) 75 (1.99)
Mean duration of follow-up for analysis (years)
Primary event 4.032 4.406
Secondary event 3.770 4.216
*Either hyperglycemia or hypoglycemia. **Either hyperglycemia, hypoglycemia, or infection (see Supple-
mentary Data for diagnostic codes for infection).
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Acute complications of diabetes in schizophreniaprofessionals involved in their care and
well-being (22). These studies combined
with the current results suggest that an
increased number of physician visits in a
system where there is no ﬁnancial cost to
thepatientmaynotbethesolution.Rather,
the focus may require a shift to altering the
content of physician encounters and
improving coordination of care with a
more holistic approach.
This study has limitations. Although
the use of administrative databases allows
for analysis of a large population-based
cohort, the databases lack comprehensive
clinical and laboratory data or medica-
tions.Itisimportanttoknowtheextentto
which antipsychotics play a role in DM
complications, as well as what therapies
arebeingusedtotreatDM.Schizophrenia
is a dynamic disease, with signiﬁcant
variation in symptoms. Certainly, it is
possible that people with poorer control
of their psychiatric illness are at a higher
risk of developing an acute complication
of DM. However, this study was designed
to assess the overall relationship between
schizophrenia and complications, regard-
less of the mechanism through which
schizophrenia impacts DM management.
If people with schizophrenia may
havealower thresholdforseekinghealth-
care, it is possible that they were screened
for DM more regularly than the matched
population, leading to an ascertainment
bias.Ifthisisthecase,thenthegroupwith
schizophrenia would be at an earlier stage
in the course of DM, which would be
protective against acute complications.
This study measured hospital visits
forhypo-andhyperglycemiaorinfections
morecommonamongpeoplewithDM,as
acute complications of DM. What is un-
known is whether these outcomes are
indeed complications of DM. There is a
potential for misclassiﬁcation, since this
coding system used in this study has not
been validated. If indeed there was mis-
classiﬁcation, it is likely that more people
in the group with coexisting schizophre-
nia would be miscoded, since the psychi-
atric illness is often the focus for the
physicians. However, it is very unlikely
that there would be a reason other than
DM, which would be associated with
hypo- or hyperglycemia severe enough
that it required an ED visit or hospital
admission. Therefore, the coding used is
likely biased toward the null for a differ-
ence in hypo- or hyperglycemia. Given
the biologic plausibility of hyperglycemia
increasing susceptibility to infection, and
previous literature supporting the in-
creased risk of the stated infections in
people with DM, it was thought that a
reasonable argument to evaluate this out-
comeasan acute DMcomplication.How-
ever,infectionshavenotbeenvalidatedas
an acute complication of DM. Regardless,
hospitalization for these infections is con-
sidered preventable and may be asso-
ciated with unnecessary morbidity and
ﬁnancial cost. Furthermore, these events
occurredmorefrequentlyandmorerapidly
among individuals with schizophrenia.
Thisistheﬁrststudytoevaluatethese
acute adverse events in people with coex-
isting schizophrenia and DM, in a pro-
vinciallyfundedmedicalsystem,andmay
relatetoqualityofDMcare.Theintention
of such a system is to provide equal
Table 3—HR of schizophrenia
Variable
HR (95% CI)
Primary outcome Secondary composite outcome
Univariate Adjusted model* Univariate Adjusted model*
Schizophrenia 1.74 (1.42–2.12) 1.68 (1.34–2.10) 1.62 (1.39–1.89) 1.45 (1.26–1.78)
Age 0.93 (0.84–1.02) 0.94 (0.85–1.05) 0.96 (0.89–1.03) 0.96 (0.88–1.03)
Sex ————
RUB category (%)
30 . 6 4 ( 0 . 5 1 –0.79) 0.58 (0.38–0.88) 0.55 (0.46–0.65) 0.62 (0.45–0.87)
40 . 9 5 ( 0 . 7 4 –1.22) 0.57 (0.35–0.92) 1.02 (0.85–1.23) 0.68 (0.47–1.00)
52 . 3 2 ( 1 . 7 1 –3.16) 1.01 (0.55–1.83) 2.77 (2.23–3.45) 1.25 (0.80–1.95)
Unstable condition 1.35 (1.06–1.70) 1.12 (0.83–1.51) 1.83 (1.54–2.17) 1.40 (1.12–1.74)
Income quintile ————
ODB coverage ————
Usual care provider 0.60 (0.47–0.76) 0.68 (0.53–0.88) 0.63 (0.53–0.76) 0.75 (0.62–0.90)
PC visits
Number 1.01 (1.00–1.02) 1.00 (0.99–1.01) 1.01 (1.01–1.02) 1.00 (1.00–1.01)
Annual 1.03 (1.02–1.04) 1.03 (1.03–1.04)
Annual internist visits 1.03 (1.01–1.04) 1.01 (1.00–1.01)
*Model adjusted for age; sex; RUB categories 3, 4, and 5; presence of a chronic unstable condition (unstable condition); income quintile; ODB (Ontario Drug Beneﬁt
Program) coverage; presence of a usual care provider; and number of visits to a PC (primary care) physician in the year preceding diabetes diagnosis (number of PC
visits).
Figure 1—Event rates.
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Becker and Huxmedical care to the entire population.
However, these results raise the question
o fw h e t h e rD Mc a r ei si n d e e de q u i t a b l e
when access is not theissue. Theseresults
underscore the importance of addressing
the needs of subpopulations with DM,
particularly those that may be vulnerable
to adverse outcomes. Future studies are
warranted to explore further factors that
contribute to acute DM complications in
people with schizophrenia and to evalu-
ate delivery models, which could mitigate
such outcomes.
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